
Please try another search
By Davit Kirakosyan
Wells Fargo upgraded Amgen (NASDAQ:AMGN) and Eli Lilly (NYSE:LLY) while downgrading Merck (NYSE:MRK).
Amgen was upgraded to Overweight from Equal Weight with a price target of $265.00 (from $275.00) as the firm believes the pessimism related to the company post-Horizon Therapeutics (NASDAQ:HZNP) deal has caused weakness, and it now sees the stock trading approximately 7-8% below the worst-case scenario.
“After combining AMGN-HZNP, we see FV of the company at $247 in a no-Tepezza US growth scenario and modest growth in other parts; the stock is trading below this level. Our base case assumes modest US growth and $5B peak sales for HZNP which is much lower than prior HZNP guidance of $6.5B peak,” said the firm.
Shares gained more than 2% today.
Eli Lilly was upgraded to Overweight from Equal Weight with a price target of $375.00 (from $360.00) as recent weakness creates a buying opportunity.
The firm’s previous Equal Weight thesis was based on unfavorable risk/reward for donanemab Alzheimer's data in H1/23 and the stock being priced to perfection for diabetes/obesity franchise.
Wells Fargo believes that the stock, being down 18% (S&P 500 -5%) without fundamental change, presents a good opportunity, given a good R&D engine, absence of near-to-medium-term loss of exclusivity, and that it is not dependent on M&A for growth.
Shares rose 3% today.
Meanwhile, Merck was downgraded to Equal Weight from Overweight with a price target of $115.00 as the firm believes with the recent appreciation of stock, Merck seems fairly valued at ~16x 2023 PE given that it still has Keytruda-related LOE issues to solve.
Shares fell nearly 2% today.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.